Rapamycin (Sirolimus) Overdose and Accidental Excess Dose

How Sirolimus Works: The mTOR Pathway and Dose-Response Curve

Sirolimus binds the intracellular protein FKBP12, and this complex directly inhibits the mammalian target of rapamycin complex 1 (mTORC1), a serine/threonine kinase that regulates cell growth, proliferation, and autophagy 1. At transplant-level daily doses (2 to 5 mg/day), sirolimus suppresses T-cell activation by blocking interleukin-2 signal transduction, preventing graft rejection 2.

The dose-response relationship is nonlinear. Trough concentrations above 15 ng/mL correlate with exponentially rising toxicity risk, particularly bone marrow suppression and metabolic disruption 3. This matters because sirolimus has a narrow therapeutic index and high interpatient pharmacokinetic variability. CYP3A4 and P-glycoprotein govern its metabolism, so drug interactions with ketoconazole, erythromycin, grapefruit juice, or rifampin can push trough levels into toxic territory even without an actual overdose 2.

For off-label longevity use, weekly dosing of 3 to 6 mg produces intermittent mTORC1 inhibition with peak-to-trough cycling that avoids the sustained mTORC2 suppression seen at transplant doses. The PEARL trial (N=150) demonstrated that 5 mg weekly sirolimus for 12 months improved self-reported health outcomes and immune function in healthy adults aged 50 to 85 without dose-limiting toxicity in most participants 4. That weekly regimen keeps trough levels well below 5 ng/mL, a fundamentally different exposure profile than the 12 to 20 ng/mL sustained troughs in transplant patients.

Recognizing a Sirolimus Overdose: Clinical Presentation

The clinical picture depends on how much was taken, and symptoms may not appear for 24 to 72 hours. This delay catches patients off guard. The 62-hour half-life means peak toxicity can trail ingestion by two or more days 2.

Hematologic toxicity dominates the overdose presentation. Thrombocytopenia (platelets <100,000/µL) appears first, often within 3 to 5 days, followed by leukopenia and anemia 5. In a case series of 35 renal transplant patients with supratherapeutic levels (mean trough 28.4 ng/mL), 71% developed significant thrombocytopenia requiring dose interruption 3.

Metabolic effects include acute hypertriglyceridemia (triglycerides exceeding 500 mg/dL have been documented at toxic troughs) and hypercholesterolemia 6. These lipid derangements can persist for one to three weeks after a single large ingestion due to ongoing mTORC1-mediated suppression of lipoprotein lipase activity.

Mucocutaneous and gastrointestinal symptoms round out the picture: oral ulcers, nausea, diarrhea, and abdominal pain. Stomatitis occurs in roughly 20% of transplant patients at therapeutic levels and is nearly universal at toxic exposures 2.

Hepatotoxicity with elevated transaminases has been reported but is uncommon. Renal function is typically preserved, which distinguishes sirolimus toxicity from calcineurin inhibitor overdose.

Accidental Excess Dosing Scenarios

Most sirolimus overdose events are not dramatic single-ingestion emergencies. They fall into three common patterns.

Drug interaction-driven toxicity is the most frequent. A transplant patient stable on sirolimus 2 mg/day starts a course of clarithromycin for a respiratory infection. Clarithromycin inhibits CYP3A4, and within 3 to 5 days the sirolimus trough climbs from 8 ng/mL to 32 ng/mL. The FDA label explicitly warns that strong CYP3A4 inhibitors can increase sirolimus AUC by 350 to 1,100% 2.

Dosing confusion occurs when patients mix up daily transplant doses with weekly longevity protocols, or vice versa. A patient prescribed 5 mg weekly for off-label use who mistakenly takes 5 mg daily for a week accumulates roughly 35 mg over seven days instead of 5 mg. Given the long half-life and tissue accumulation, this can produce sustained troughs above 20 ng/mL.

Pediatric accidental ingestion is rare but reported in poison control databases. The American Association of Poison Control Centers documented 47 sirolimus exposure calls in 2022, with 12 involving children under 6 years 7.

Immediate Management Protocol

There is no antidote for sirolimus. The drug is 92% protein-bound and has a large volume of distribution (12 L/kg), making hemodialysis ineffective 2. Management is supportive and monitoring-intensive.

Within the first two hours, activated charcoal (1 g/kg, maximum 50 g in adults) can reduce absorption. A pharmacokinetic study demonstrated that activated charcoal administered within one hour of sirolimus ingestion reduced bioavailability by approximately 30 to 40% 8. Beyond two hours, the benefit drops significantly because sirolimus is rapidly absorbed from the gastrointestinal tract with a Tmax of 1 to 2 hours.

Gastric lavage is not routinely recommended and should only be considered for massive ingestions (estimated dose exceeding 50 mg) presenting within one hour.

Baseline labs at presentation should include: complete blood count with differential, comprehensive metabolic panel, fasting lipid panel, hepatic function tests, and a stat sirolimus trough level. Repeat the sirolimus trough at 24 and 72 hours to capture the post-distribution concentration and determine the trajectory 9.

Dr. William Bennett, former chair of pharmacology at Oregon Health & Science University, noted: "With sirolimus toxicity, patience is the treatment. The half-life dictates the timeline, and you cannot accelerate elimination. Serial monitoring and supportive care are the entire playbook."

Monitoring Timeline and Laboratory Surveillance

The extended half-life demands a monitoring schedule that outlasts the patient's acute symptoms.

Days 1 through 3: check CBC and sirolimus trough every 24 hours. Platelets typically begin declining by day 3. If the initial trough exceeds 30 ng/mL, consider inpatient observation.

Days 4 through 7: platelet nadir usually occurs between days 5 and 7 5. White blood cell nadir follows 1 to 2 days later. Check CBC every 48 hours. Monitor triglycerides and LDL at day 5.

Days 8 through 14: troughs should be approaching the therapeutic range or below. CBC recovery begins. Continue monitoring every 3 to 4 days until platelets exceed 100,000/µL and the ANC exceeds 1,500/µL.

Beyond day 14: lipid normalization may lag behind hematologic recovery. Recheck a fasting lipid panel at 3 and 6 weeks post-event.

For patients on chronic sirolimus therapy, do not restart the drug until the trough falls below 12 ng/mL and blood counts have recovered to at least 75% of baseline values 10.

Managing Specific Toxicities

Thrombocytopenia: platelet transfusion is indicated only for active bleeding or counts below 10,000/µL in the absence of bleeding risk factors. Prophylactic transfusion thresholds should follow institutional guidelines, typically <10,000/µL for stable patients or <20,000/µL with fever or concurrent anticoagulation 11.

Severe hypertriglyceridemia: triglycerides above 500 mg/dL carry pancreatitis risk. Initiate a fibrate (fenofibrate 145 mg daily) and dietary fat restriction. If triglycerides exceed 1 to 000 mg/dL, consider insulin infusion or plasmapheresis in an ICU setting 12.

Oral mucositis: topical dexamethasone rinse (0.5 mg/5 mL, swish and spit four times daily) provides symptom relief. Avoid systemic steroids, which compound the immunosuppression. The mTOR inhibitor-associated stomatitis (mIAS) working group recommends this topical approach as first-line 13.

Infection risk: the immunosuppressive window extends well beyond trough normalization. Advise patients to avoid crowds and report fevers above 100.4°F for 2 to 3 weeks after toxic exposure. Prophylactic antimicrobials are not routinely indicated unless the ANC drops below 500/µL, at which point neutropenic precautions and consideration of G-CSF are warranted.

Off-Label Longevity Dosing: Is Overdose Realistic?

The weekly longevity dosing protocol carries substantially lower overdose risk than daily transplant regimens. A typical weekly dose of 5 mg produces peak concentrations around 15 to 25 ng/mL that fall below 2 ng/mL before the next dose 4. Even a double dose (10 mg in a single sitting) would produce a transient peak comparable to routine transplant dosing and is unlikely to cause clinically significant toxicity in an otherwise healthy individual.

The real danger for longevity users is the drug interaction scenario. Dr. Matt Kaeberlein, a biogerontologist formerly at the University of Washington, has stated: "The longevity community needs to understand that the weekly dose is safe in isolation, but adding a CYP3A4 inhibitor can turn a benign regimen into a toxic one within days."

A longevity patient who inadvertently takes a 5 mg dose daily for a week faces meaningful risk. Five consecutive daily doses of 5 mg would produce steady-state troughs in the 15 to 25 ng/mL range based on population pharmacokinetic modeling, well into the toxicity zone 14. The PEARL trial protocol included weekly trough monitoring during the initial dosing phase precisely to catch such accumulation early 4.

When to Go to the Emergency Department

Not every excess dose requires emergency care. Use this triage framework.

Go to the ED immediately if: the ingested dose exceeds 25 mg in a single event, the patient is a child under 12, the patient is already on immunosuppressive therapy, or the patient develops signs of bleeding (petechiae, hematuria, melena) within the first 48 hours.

Call your prescriber the same day if: you accidentally doubled a weekly longevity dose (total <15 mg), you realized you took daily instead of weekly dosing for 2 to 3 days, or you started a new medication that may interact with sirolimus.

Monitor at home with next-day follow-up if: you took one extra weekly dose (<10 mg total weekly exposure) and have no symptoms, no concurrent CYP3A4 inhibitors, and no pre-existing cytopenias.

Poison Control and Reporting

The U.S. Poison Control hotline (1-800-222-1222) should be contacted for any confirmed or suspected sirolimus overdose. Poison control specialists can provide real-time dosing calculations and recommend the appropriate level of care based on the specific clinical scenario 15.

Report adverse events and overdoses to the FDA MedWatch program (1-800-FDA-1088 or online at fda.gov/medwatch). Reporting is especially important for off-label longevity use cases, where the safety database remains thin compared to transplant indications.

Sirolimus trough levels drawn within 72 hours of the suspected overdose are the single most useful data point for both poison control guidance and subsequent clinical decision-making. Bring the trough result, a list of all concurrent medications, and the estimated time and amount of ingestion to every clinical encounter following the event.